Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: Results from a retrospective matched-pair analysis

Anticancer Research

Volumn 34, Issue 1, 2014, Pages 227-233

  Gampenrieder, Simon Peter ^a,b   Romeder, Franz ^a,b   Muß, Claudia ^a,b   Pircher, Magdalena ^a,b   Ressler, Sigrun ^a,b   Rinnerthaler, Gabriel ^a,b   Bartsch, Rupert ^c   Sattlberger, Claudia ^d   Mlineritsch, Brigitte ^a,b   Greil, Richard ^a,b  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b III rd Medical Department with Hematology Medical Oncology Hemostasis Rheumatology and Infectious Diseases Oncologic Center Center for Clinical Cancer and Immunology Trials   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Hospital of Vöcklabruck   (Austria)

Author keywords

Bevacizumab; Breast cancer; Hypertension; Matched pair; Metastatic disease; Predictive markers; Survival

Indexed keywords

BEVACIZUMAB; CAPECITABINE; DOCETAXEL; EPIRUBICIN; GEMCITABINE; PACLITAXEL; TRASTUZUMAB; ANGIOGENESIS INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; AGED; ANAPHYLAXIS; ARTICLE; BLEEDING; BREAST METASTASIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RETROSPECTIVE STUDY; SEPSIS; THROMBOEMBOLISM; TREATMENT RESPONSE; BREAST CANCER; BREAST TUMOR; CANCER STAGING; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; LYMPH NODE METASTASIS; MATCHED PAIR; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE MARKERS; PROGNOSIS; SURVIVAL; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY;

BEVACIZUMAB; BREAST CANCER; HYPERTENSION; MATCHED PAIR; METASTATIC DISEASE; PREDICTIVE MARKERS; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84897023959     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Cancer Therapy Evaluation Program NCI. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Online Instructions and Guidelines. http://ctep.cancer.gov/protocol Development/electronic-applications/ctc.htm. Accessed December 01, 2013.
2. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V and Rugo HS: RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29: 4286-4293, 2011.
3. Cortes J, Calvo V, Ramirez-Merino N, O'Shaughnessy J, Brufsky A, Robert N, Vidal M, Munoz E, Perez J, Dawood S, Saura C, Di Cosimo S, Gonzalez-Martin A, Bellet M, Silva OE, Miles D, Llombart A and Baselga J: Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol 23: 1130-1137, 2012.
4. De Stefano A, Carlomagno C, Pepe S, Bianco R and De Placido S: Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol 68: 1207-1213, 2011.
5. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European J Cancer 45: 228-247, 2009.
6. Etienne-Grimaldi MC, Formento P, Degeorges A, Pierga JY, Delva R, Pivot X, Dalenc F, Espie M, Veyret C, Formento JL, Francoual M, Piutti M, de Cremoux P and Milano G: Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. Br J Clin Pharmacol 71: 921-928, 2011.
7. Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C and Semiglazov V: AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer. J Clin Oncol 31: 1719-1725, 2013.
8. Hurwitz HI, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, Chen D and Rosen O: Analysis of Early Hypertension and Clinical Outcome With Bevacizumab: Results From Seven Phase III Studies. Oncologist 18: 273-280, 2013.
9. Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, Yesilyurt BT, Devlieger R, Verslype C, Tejpar S, Wildiers H, de Haas S, Carmeliet P, Scherer SJ and Van Cutsem E: VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. The lancet oncology 13: 724-733, 2012.
10. Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Messinger D and Zielinski C: Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. The lancet oncology 14: 125-133, 2013.
11. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A and Romieu G: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28: 3239-3247, 2010.
12. Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortes J, Delmar PR and Scherer SJ: Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer 2013.
13. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D and Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666-2676, 2007.
14. Mir O, Coriat R, Cabanes L, Ropert S, Billemont B, Alexandre J, Durand JP, Treluyer JM, Knebelmann B and Goldwasser F: An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. The oncologist 16: 1325-1332, 2011.
15. Nazer B, Humphreys BD and Moslehi J: Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 124: 1687-1691, 2011.
16. Neagoe PE, Lemieux C and Sirois MG: Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer. J Biol Chem 280: 9904-9912, 2005.
17. Olsson AK, Dimberg A, Kreuger J and Claesson-Welsh L: VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371, 2006.
18. Osterlund P, Soveri LM, Isoniemi H, Poussa T, Alanko T and Bono P: Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer 104: 599-604, 2011.
19. Preusser M, Fulop G, Berghoff AS, Heinzl H, Steger GG, Greil R, Zielinski CC and Bartsch R: Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer. The oncologist 17: e13-17, 2012.
20. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J and Small EJ: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28: 2137-2143, 2010.
21. Robert NJ, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov O, Perez E, Yardley D, Zhou X and Phan S: RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 27: 15s 2009.
22. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C and Cascinu S: Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 20: 227-230, 2009.
23. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S and Miller KD: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26: 4672-4678, 2008.
24. Smith I, Pierga JY, Biganzoli L, Cortes-Funes H, Thomssen C, Saracchini S, Nisenbaum B, Pelaez I, Duenne AA and Pritchard KI: Final overall survival results and effect of prolonged (>/=1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial. Breast Cancer Res Treat 130: 133-143, 2011.
25. Syrigos KN, Karapanagiotou E, Boura P, Manegold C and Harrington K: Bevacizumab-induced hypertension: pathogenesis and management. BioDrugs 25: 159-169, 2011.